Oocyte maturation remains an enigmatic process that is generally understood to span the time from when messages initiate germinal vesicle breakdown (GVBD) to completion of the nuclear changes resulting in expulsion of the first polar body. The process of maturation encompasses a complex series of molecular and structural events, culminating in the arrest of the oocyte chromosomes on the metaphase II plate in anticipation of sperm penetration and activation for fertilization. There is no agreed assay for the completion of oocyte maturation, other than the full developmental competence of the fertilized oocyte to fully formed live born offspring. Completion of the nuclear changes to produce a metaphase II oocyte does not identify developmental competence and does not reflect the molecular and structural maturity of an oocyte, which is sometimes termed cytoplasmic maturation. It is well known that oocytes will progress spontaneously through the nuclear changes characteristic of oocyte maturation when they are liberated from the antral follicle and cultured in vitro (Pincus and Enzmann, 1935; Edwards, 1965). GVBD may be observed in oocytes in advanced stages of follicular atresia when follicular support cells have died. Hence progression of meiosis to metaphase I or II could be representative of either oocyte degeneration or oocyte maturation. Studies in the mid-1970s by Thibault et al. (1975) and Moor and Trounson (1977) showed that, in species such as rabbits and sheep that have an obligatory phase of protein synthesis during maturation, a complete follicle was necessary to mature oocytes fully. By maintaining the primary elements of follicular culture and retaining granulosa cell viability and function, Staigmiller and Moor (1984) were able to retain maturation and developmental competence of sheep oocyte-cumulus cell complexes in culture when they were removed from the follicular environment. Complete maturation of oocytes is essential for the developmental competence of embryos. Any interventions in the growth phase of the oocyte and the follicle in the ovary will affect oocyte maturation, fertilization and subsequent embryo development. Oocyte size is associated with maturation and embryo development in most species examined and this may indicate that a certain size is necessary to initiate the molecular cascade of normal nuclear and cytoplasmic maturation. The minimum size of follicle required for developmental competence in humans is 5−7 mm in diameter. Maturation in vitro can be accomplished in humans, but is associated with a loss of developmental competence unless the oocyte is near completion of its preovulatory growth phase. This loss of developmental competence is associated with the absence of specific proteins in oocytes cultured to metaphase II in vitro. The composition of culture medium used successfully for maturation of human oocytes is surprisingly similar to that originally developed for maturation of oocytes in follicle culture in vitro. The presence of follicle support cells in culture is necessary for the gonadotrophin-mediated response required to mature oocytes in vitro. Gonadotrophin concentration and the sequence of FSH and FSH−LH exposure may be important for human oocytes, particularly those not exposed to the gonadotrophin surge in vivo. More research is needed to describe the molecular and cellular events, the presence of checkpoints and the role of gene expression, translation and protein uptake on completing oocyte maturation in vitro and in vivo. In the meantime, there are very clear applications for maturing oocytes in human reproductive medicine and the success rates achieved in some of these special applications are clinically valuable.
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Complete maturation of oocytes is essential for the developmental competence of embryos. Any interventions in the growth phase of the oocyte and the follicle in the ovary will affect oocyte maturation, fertilization and subsequent embryo development.
Oocyte size is associated with maturation and embryo development in most species examined and this may indicate that a certain size is necessary to initiate the molecular cascade of normal nuclear and cytoplasmic maturation. The minimum size of follicle required for developmental competence in humans is 5−7 mm in diameter. Maturation in vitro can be accomplished in humans, but is associated with a loss of developmental competence unless the oocyte is near completion of its preovulatory growth phase. This loss of developmental competence is associated with the absence of specific proteins in oocytes cultured to metaphase II in vitro. The composition of culture medium used successfully for maturation of human oocytes is surprisingly similar to that originally developed for maturation of oocytes in follicle culture in vitro. The presence of follicle support cells in culture is necessary for the gonadotrophin-mediated response required to mature oocytes in vitro. Gonadotrophin concentration and the sequence of FSH and FSH−LH exposure may be important for human oocytes, particularly those not exposed to the gonadotrophin surge in vivo. More research is needed to describe the molecular and cellular events, the presence of checkpoints and the role of gene expression, translation and protein uptake on completing oocyte maturation in vitro and in vivo. In the meantime, there are very clear applications for maturing oocytes in human reproductive medicine and the success rates achieved in some of these special applications are clinically valuable.
Follicular size, oocyte maturation and developmental competence
Follicular development in monovular species is characterized by recruitment of primordial follicles for an extended period of follicular growth, selection of a dominant follicle destined for ovulation, and atresia of the remaining cohort. Follicle development is a continuum that begins at birth and continues to the end of reproductive life. The human oocyte grows from a diameter of 35 m to a final diameter of 120 m over several months (Gosden and Bownes, 1995; Gougeon, 1996) . During this period the oocyte synthesizes and stores mRNA and proteins essential for the completion of maturation and for the subsequent acquisition of embryo developmental competence and ongoing viability. In humans, during the late luteal phase of the preceding menstrual cycle, the largest non-atretic follicles range in size between 2 and 5 mm in diameter (Gougeon and Lefevre, 1983; McNatty et al., 1983) . In the early follicular phase, the largest follicle ranges in size from 5.5 to 8.2 mm and this is usually the follicle that achieves dominance and continues growth to ovulation (Gougeon and Lefevre, 1983) . The preovulatory follicle develops to a diameter of 18.8 Ϯ 0.5 mm by the late follicular phase (Gougeon and Lefevre, 1983) and expands rapidly after the mid-cycle LH surge to a diameter of у 25 mm. Antrum formation in the rodent follicle occurs at about the time oocytes complete their growth and the oocyte has acquired the capacity to resume meiosis (Eppig and Schroeder, 1989) . In mice, a polyovular species, oocytes from early antral follicles are competent to resume the first meiotic division (Sorensen and Wassarman, 1976) and when isolated from the follicle undergo spontaneous resumption of meiosis. However, competence of oocytes to complete maturation beyond the first meiotic division is not conferred in mice until the follicle is much larger (Eppig and Schroeder, 1989) . Developmental competence, as shown by the ability to undergo fertilization and develop to the blastocyst stage, is dependent on both the size of the follicle and the size of the oocyte (Eppig et al., 1992) .
The capacity for meiotic competence in rabbits (Bae and Foote, 1975) , cows (Sato et al., 1977) , pigs (Tsafiri and Channing, 1975) , sheep (Moor and Trounson, 1977) , goats (Martino et al., 1994) , horses (Goudet et al., 1997) and rhesus monkeys (Schramm et al., 1993) increases with follicle size and is not strictly correlated with antrum formation or maximum oocyte diameter, which occurs later. Marmoset monkeys are similar to mice in that meiotic competence occurs concomitantly with antrum formation (Adachi et al., 1982; Gilchrist et al., 1995) . However, follicular antrum formation occurs at different stages of folliculogenesis in different species. Antrum formation occurs in human and bovine follicles at 2% of the final ovulatory diameter (Motlik and Fulka, 1986; Greenwald and Terranova, 1988) . In rhesus monkeys, an antrum appears at 3% (Greenwald and Terranova, 1988) , in pigs at 4.5% (Motlik and Fulka, 1986) and in marmoset monkeys at 15% of final ovulatory diameter (Gilchrist et al., 1995) . Consequently it is also more appropriate to consider meiotic competence in relation to follicular diameter as a proportion of ovulatory size. Marmoset monkey oocytes from follicles at 2% of final ovulatory diameter are meiotically incompetent (Gilchrist et al., 1995) .
In all non-rodent species studied, the ability of oocytes to resume meiosis is acquired when the diameter of the follicle is about 9-13% of the ovulatory diameter, a stage by which oocyte growth is completed (Gilchrist et al., 1995) . In oocytes, the ability to complete maturation to metaphase II and developmental competence is acquired progressively with increasing follicular diameter. Goat oocytes from follicles > 5 mm in diameter undergo fertilization and develop to blastocysts at rates comparable to ovulated oocytes (Crozet et al., 1995) . Cow oocytes from follicles > 6 mm have about twice the developmental potential of oocytes from 2-6 mm follicles (Tan and Lu, 1990; McCaffrey et al., 1992; Lonergan et al., 1994) . Cow oocytes from follicles < 3 mm not only show a significantly lower rate of maturation and fertilization but also fail to cleave beyond the 8-to 16-cell stage of development (Pavlok et al., 1992; Blondin and Sirard, 1995) . Follicle diameter and oocyte diameter are significantly correlated in the cow for follicles in the range of < 1 mm to у 4 mm, and the proportion of oocytes completing maturation to metaphase II in vitro is associated with increasing oocyte diameter, at least up to 110 m in diameter. Cow oocytes < 110 m show a significant increase in the incorporation of tritiated uridine compared with larger oocytes, indicating that the smaller oocytes are in the growth phase and still actively synthesizing RNA that is essential to maturation and later development (Fair et al., 1995) . In cows, oocytes appear to acquire full meiotic competence at a diameter of 115 m and attain the competence for preimplantation embryonic development to expanded and hatching blastocysts at a diameter of 120 m (Otoi et al., 1997) .
Human and macaque oocytes resume spontaneous meiosis in vitro at a very low rate compared with other species (Edwards, 1965) . The explanation for this observation could be that meiotic competence occurs relatively late in the growth phase or that maturation requires both stimulation and removal of inhibition (Lefevre et al., 1987) . The human oocyte has a size-dependent ability to resume meiosis and complete maturation in vitro and this increases significantly as the oocyte increases in diameter from 90 to 120 m (Durinzi et al., 1995) . Furthermore, this size-dependent ability for meiotic competence may also depend on the size of the follicle and the stage of the menstrual cycle. Oocytes retrieved from the follicular phase of the menstrual cycle from follicles of 9-15 mm in diameter complete meiotic maturation to metaphase II at a higher rate than oocytes from follicles of 3-4 mm in diameter (Tsuji et al., 1985; Whitacre et al., 1998) . Wynn et al. (1998) reported that 5 mm was the minimum follicle diameter from which oocytes would mature in vitro. Oocytes retrieved from follicles in the luteal phase of the menstrual cycle completed maturation at the same rate irrespective of follicle size (Tsuji et al., 1985) .
Many studies have been undertaken to determine the effect of follicle size on the maturational status and subsequent fertilization, development and competence of the human oocytes from gonadotrophin-stimulated ovulatory cycles. The incidence of mature oocytes recovered after superovulation with human menopausal gonadotrophin (hMG) and human chorionic gonadotrophin (hCG) increases with increasing follicular size (Simonetti et al., 1985) . The proportion of mature oocytes from follicles у 15 mm in diameter remained constant. In follicles < 15 mm in diameter there was a significant reduction in mature oocytes; only 30% of oocytes mature in follicles of 12-14 mm and 9% in follicles < 11 mm in diameter (Scott et al., 1989) . There is widespread opinion that after gonadotrophin stimulation the fertilization rate is lower in oocytes obtained from follicles < 10 mm in diameter than in those obtained from larger follicles (Wittmaack et al., 1994; Dubey et al., 1995; Salha et al., 1998a) . This low fertilization rate is probably due to the increase in immature oocytes recovered from smaller follicles. Fertilization has been reported to increase progressively with an increase in follicle diameter from 10 mm (Dubey et al., 1995) , although others have reported that once a follicle has reached 10-12 mm in diameter the fertilization rate remains relatively constant with progressive follicle growth (Haines and Emes, 1991; Wittmaack et al., 1994; Salha et al., 1998a) . Embryo cleavage rates were reported to be significantly decreased or not significantly different for oocytes obtained from follicles < 12 mm in diameter. Embryo quality (assessed on morphology of the blastomeres and degree of fragmentation), implantation, pregnancy and birth rates appear to be independent of follicle size in stimulated cycles (Wittmaack et al., 1994; Salha et al., 1998a) .
In monovular species, one or two follicles become dominant in the final growth phase, leading to a marked increase in the ratio of oestrogen:androgen of the dominant follicle or follicles. The remaining cohort of antral follicles remain androgen dominated and ultimately undergo atresia. Prolonged exposure to androgens in sub-dominant follicles may have an adverse effect on oocyte viability and developmental competence (Anderiesz and Trounson, 1995) . In humans, the dominant follicle can usually be recognized by ultrasonography when it has reached 10 mm in diameter (Fauser and van Heusden, 1997) . In a large study of gonadotrophin-stimulated IVF cycles, Wittmaack et al. (1994) reported that the size of the leading follicle did not affect the fertilization and cleavage rates of cohort oocytes. In contrast, Russell (1998) reported a marked decrease in the rates of maturation, fertilization and transfer among cycles in which immature oocytes were retrieved when a dominant follicle of у 14 mm was present at the time of retrieval.
Studies in this laboratory indicate that oocytes retrieved from follicles in an untreated natural cycle, or from a cycle in which clomiphene citrate is used for minimal ovarian stimulation, are capable of complete development to the blastocyst stage after administration of exogenous hCG (5000 iu) to induce maturation in vivo as early as day 8 of the menstrual cycle with a leading follicle diameter of 12 mm (Table 1) . Mature oocytes were recovered by transvaginal aspiration 36 h after hCG administration. Development of embryos in the cohort follicles in these cycles appeared to be independent of the diameter of the leading follicle at the time of hCG injection ( Table 2 ). Development to the blastocyst stage was observed from the smallest follicle (6 mm) retrieved in this study (Fig. 1) . A live birth resulted from the transfer of a single blastocyst from a follicle measuring only 11 mm at the time of hCG injection when the leading follicle was 19 mm in diameter. Sixty-one per cent of all the oocytes retrieved and fertilized developed to the blastocyst stage, a number comparable to that observed in gonadotrophin-stimulated cycles (hMG or FSH and hCG treated) using identical culture conditions (Jones et al., 1998) . In our studies, patients with regular menstrual cycles undergoing an in vitro maturation cycle have a leading follicle > 9 mm in diameter by days 8−13 of the menstrual cycle in 79% of cases, but anovulatory or irregularly ovulating patients with polycystic ovarian disease syndrome (PCOS) rarely have a leading follicle > 9 mm in diameter at the time of immature oocyte recovery. These data indicate that the developmental competence of the in vitro matured oocyte must be compromised by some inherent but unidentified problem in the maturation process in vitro rather than being directly related to reduced follicle size, at least for follicles > 6 mm in diameter.
Source of oocytes used for in vitro oocyte maturation
Oocytes of farm animals can be obtained from abattoirs after slaughter of the animals. Ovaries are recovered from the animals and kept in warm PBS for transport to the laboratory. Oocytes are then aspirated from the antral follicles visible on the surface of the ovary or identified under the dissecting microscope from minced ovarian tissue. Cows in different phases of the ovulatory cycle (follicular and luteal) or even pregnant at the time they are killed do not show any marked difference in the maturational competence of oocytes. Maturation in vitro of cow oocytes recovered by transvaginal ultrasonography show comparable developmental competence to oocytes matured in the ovaries of animals and grown to blastocysts in the donor (Bousquet et al., 1999) . In this large scale study, the donor cows were given 4 days of FSH treatment (total of 400 mg FSH) after removal of the dominant follicle and the oocytes were recovered 44−48 h after the end of FSH treatment. Oocyte developmental competence was not compromised by either maturation in vitro, IVF or embryo culture (Fig. 2) . The medium used for maturation was tis-sue culture medium 199 (TCM 199) with 10% fetal bovine serum (FBS), 0.5 g FSH ml -1 , 5 g LH ml -1 and 1 g oestradiol ml -1 , and is similar to that used by Moor and Trounson (1977) for the successful maturation of sheep oocytes in follicle culture. A detailed consideration of the gonadotrophin, steroid and growth factor benefits for bovine oocyte maturation (Bevers et al., 1997) indicates that the major benefits are from components that are already present in the TCM 199 medium described above. This finding indicates that the factors governing oocyte maturation in vitro are primarily intrinsic to the follicle, oocyte−cumulus mass or the oocyte itself. Surprisingly, only relatively minor changes in developmental competence of animal and human oocytes have been recorded in numerous studies on culture media and conditions for oocyte maturation. Immature oocytes from PCOS patients Methods were developed by Trounson et al. (1994) for the recovery of oocytes from the ovaries of patients with PCOS in which the dominance of a particular follicle fails to occur and the cohort of growing follicles accumulates in the cortex. Most of these follicles are about 5 mm in diameter (range 3−8 mm) and remain under an androgendominated environment due to increased thecal cell secretion of androgens and a blockage of aromatization in the granulosa cell compartments . It is not uncommon for у 20 small to medium sized antral follicles to be present in each ovary of PCOS patients. When oocytes are recovered by transvaginal guided ultrasonography they can be readily identified and will undergo nuclear maturation in a number of different culture media, undergo fertilization after insemination or intracytoplasmic sperm injection (ICSI) and begin cleavage in culture (Trounson et al., 1994 (Trounson et al., , 1998 . Compared with oocytes recovered from regularly cyclic non-PCOS women, oocyte maturation, fertilization and embryo development in culture is significantly retarded (Barnes et al., 1996) . However, babies have been born from the cleaving embryos and blastocysts produced as a result of in vitro oocyte maturation (Trounson et al., 1994; Barnes et al., 1995) although implantation rates are generally low (Trounson et al., 1998) . Barnes et al. (1996) also suggested that oocytes from PCOS patients were at a disadvantage because of the abnormal endocrine environment and stasis of follicular growth. It is of interest to note that most of the follicles in these PCOS patients are not atretic , nor does follicular atresia appear to reduce the developmental competence of human oocytes (Barnes et al., 1996) . A marked improvement in viability of embryos produced from in vitro maturation of oocytes derived from PCOS patients was reported by Cha and Chian (1998). They recovered 910 oocytes from 72 PCOS cases (12.6 oocytes per case) and of 832 oocytes cultured, 499 (60%) matured to metaphase II. Eighty per cent of the metaphase II oocytes underwent fertilization and 306 embryos were transferred to 64 patients (4.7 embryos per patient) to yield 16 pregnancies (one twin pregnancy). The overall implantation rate was 5.6% per embryo transferred, but notably a mixture of pronuclear oocytes and early cleavage stage embryos was transferred in this study.
The media used to mature human oocytes by Cha and Chian (1998) was TCM 199 with 20% FBS and contained 10 iu equine chorionic gonadotrophin (eCG) ml -1 and 10 iu hCG ml -1 . eCG has approximately 50:50 FSH and LH bioactivity. This medium is again very much like the original follicle culture medium of Moor and Trounson (1977) and, like the successful bovine oocyte maturation medium, contains a large quantity of FBS. FBS is considered crucial for bovine oocyte maturation and may also contain factors essential for human oocyte maturation (Barnes, 1999) . A medium designed to meet the nutritional and maturational needs of human oocytes based on a detailed review of oocyte metabolism and developmental competence (human oocyte maturation (HOM) medium; Table 3 ) has been tested for maturation, fertilization and embryo development of oocytes recovered from PCOS patients without any apparent benefit for these parameters compared with a commonly used commercial amniocyte culture medium that contains bovine serum (Chang's medium; Trounson et al., 1998) . There is a need to explore more extensively the role of culture medium and additives 
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(2) (1) (1) Follicle diameter on day of hCG injection (mm) for maturation, particularly the importance and replacement of the FBS component with an appropriate combination of growth factors and other components that are present in the follicular milieu. FBS continues to be used with some success despite the concerns about potential transmission of infectious agents. From this point of view, HOM medium may be preferable for the clinical application of oocyte maturation in vitro.
A rather unusual variant of treatment for PCOS patients with irregular menstrual cycles was reported by Chian et al. (1999a,b) and involves oocyte maturation in vitro. The patients were given intravaginal progesterone (300 mg once a day) for 10 days to induce withdrawal bleeding and 10-14 days later were given 10 000 iu hCG and the oocytes that were visible by transvaginal ultrasonography recovered from antral follicles. The oocytes were matured in vitro for 24-48 h in TCM 199 containing the patient's own serum (20%), 25 mmol pyruvic acid l −1 and 75 miu hMG. Of 25 patient treatment cycles, ten resulted in pregnancy (40%) when an average of 2.9 embryos were transferred. The authors claimed that priming with hCG before oocyte recovery increased the developmental competence of the immature oocytes recovered. However, no data were provided to show that the oocytes were immature after hCG injection. Our observations reported earlier in this review show that the oocytes recovered are mature 36 h after hCG, even from follicles as small as 6 mm in diameter at the time of hCG injection. In a further study (Chian et al., 2000) , the authors showed that 46% of oocytes were already maturing in hCG primed patients and the oocytes completed meiosis 12-24 h ahead of oocytes from unprimed (no hCG administration) patients. The final outcomes of fertilization, embryo development and pregnancy rates for hCG primed and unprimed patients were not significantly different.
Oocyte maturation after superovulation of IVF patients with gonadotrophins (hMG, FSH and hCG)
Normal methods for superovulation in human IVF entail the control of endogenous gonadotrophins, usually by suppression of their secretion and release from the pituitary by gonadotrophin releasing hormone (GnRH) agonists or antagonists. Multiple follicular growth is induced by administration of exogenous FSH and the final phase of oocyte maturation is induced by hCG (Eldar-Geva et al., 1999) . However, about 5−7% of oocytes recovered after superovulation for IVF are immature at the germinal vesicle (GV) stage and require further maturation in vitro (see Table 4 ). Some oocytes will complete maturation spontaneously in culture in vitro over 4−6 h before insemination (Osborn, 1993) and after being denuded of cumulus cells in preparation for fertilization by ICSI (De Vos et al., 1999) . Fertilization may be lower with these oocytes and their cleavage and capacity to develop to term may be reduced (De Vos et al., 1999) . The maturation of these oocytes may be considered to be delayed, and any reduced developmental competence compared with mature metaphase II oocytes may be related to the inability of the follicles to respond synchronously with other large follicles to hCG administration.
The time course for GVBD differs for GV stage oocytes recovered from superovulated IVF patients and untreated women (Cha and Chian, 1998) . After 12 h of culture 80% of GV oocytes have undergone GVBD, whereas all the oocytes recovered from untreated patients still had intact GVs (Fig. 3) . This leads to a disparity in the completion of nuclear maturation in the oocytes from both sources (Cha and Chian, 1998) . About 75% of oocytes from superovulated patients reach metaphase II by 30 h of culture, whereas 75% of oocytes from untreated patients have extruded the first polar body by 42-45 h (Fig. 3) . The difference in the onset of GVBD may be due to the priming of follicles by FSH and hCG before recovery of the 56 A. Trounson et al. Vitamins: ICN (catalogue no. 1601449) 100 ϫ solution; use 10 l per 10 ml to give 0.1 ϫ concentration. EGF: Sigma (catalogue no. E1264) 100 g per vial; prepare 100 g per 10 ml stock solution in HOM salts + 0.3% (3 mg ml −1 ) HSA. Add 10 l per 10 ml to give 10 ng ml −1 . ITS: Sigma (catalogue no. I1884) prepare 50 ml stock from one bottle and store stock frozen in working aliquots, dilute stock 1:1000 in final solution = 10 l per 10 ml.
oocytes. However, follicles that have immature oocytes after administration of large doses of hCG (5000-10 000 iu hCG) must lack sufficient blood supply to receive the ovulatory stimulus or have insufficient LH receptors to induce the oocyte maturation response in vivo (reviewed by Salha et al., 1998b) . Since many of the GV oocytes also have unexpanded cumuli, it is likely that insufficient FSH and LH is available to these follicles in vivo to induce oocyte maturation. Oocytes considered to be immature by cumulus and corona cell expansion after superovulation of IVF patients can be matured in culture without gonadotrophin or steroid supplements (Veeck et al., 1983; Dandekar et al., 1991) but the culture medium usually contains the patient's own serum and occasionally granulosa cells recovered from the same follicle or from other follicles that contained a mature oocyte. There are numerous case reports of development to term after maturation of oocytes recovered from superovulated patients without any special additives to culture medium (Nagy et al., 1996; Edirisinghe et al., 1997; Tucker et al., 1998) . Pregnancies have also been reported for IVF patients who were not given the final ovulating dose of hCG either by mistake (Liu et al., 1997) or to reduce the probability of ovarian hyperstimulation syndrome (OHSS) (Jaroudi et al., 1997; Coskun et al., 1998) . In the former case, 50 iu FSH ml -1 and 50 iu hCG ml -1 in B2 Ménézo medium was used for oocyte maturation. In the latter case, hMG and hCG were also added to the culture medium for oocyte maturation (75 miu hMG ml -1 and 500 miu hCG ml -1 in human tubal fluid or Ham's F10 culture medium supplemented with 10% synthetic serum substitute; Irvine Scientific, Santa Ana, CA). Jaroudi et al. (1999) used this procedure and reported a pregnancy rate of 9.5% and an implantation rate of 4.5% per transferred embryo.
It is interesting that oocytes appear to mature spontaneously or in the presence of gonadotrophins when patients are treated as if to recover mature oocytes for conventional IVF. However, there is very limited application for maturation in vitro in association with superovulation except to use the few immature oocytes that are recovered, or as a precaution to prevent OHSS, although in overstimulated IVF patients other strategies are available for treating this potential problem.
Pre-treatment of women with hMG or FSH for oocyte maturation Preliminary studies of the treatment of women for 1 or 3 days with recombinant human FSH (rhFSH) early in the follicular phase showed no difference in the recovery rate of oocytes, or oocyte maturation, fertilization or development in culture (Trounson et al., 1998) . This finding was confirmed by Mikkelsen et al. (1999) who also treated women for 3 days with rhFSH (150 iu once a day, days 3-5 of the cycle) and found no improvement in any parameter of oocyte recovery, maturation or developmental competence. Oocytes were matured in TCM 199 with 75 miu rhFSH ml -1 , 500 miu hCG ml -1 and 10% patient's own serum from the day of oocyte recovery. Mikkelsen et al. (1999) claimed a benefit of reduced culture period for maturation (36 versus 48 h) on implantation rates of embryos produced. However, this aspect was not tested in the same experiment. Implantation rate was 15% for oocytes matured for 36 h and 7% for oocytes matured for 48 h, for embryos transferred in the two experiments. No benefit of an abbreviated culture interval for maturing oocytes of untreated patients (24, 36 or 48 h) could be detected by Trounson et al. (1994 . Mikkelsen et al. (1999) did not observe any benefit of extending the rhFSH pre-treatment from 3 to 6 days to produce follicles > 10 mm in diameter. However, Wynn et al. (1998) administered 600 iu rhFSH to women over 5 days (300 iu on day 2, 150 iu on day 4 and 150 iu on day 6) for recovery of immature oocytes (day 7). A mean of 7.5 oocytes was recovered after rhFSH treatment compared with 5.2 oocytes from untreated women. Maturation to metaphase II was higher in rhFSH treated women (71%) compared with untreated women (44%) and hence more metaphase II oocytes resulted after rhFSH treatment (mean of 4.8 versus 2.1 for untreated women). The medium used was Eagles' minimum essential medium (EMEM) with a number of additives including 10 miu rhFSH ml -1 and 100 miu hCG ml -1 .
The failure to achieve a substantial improvement in the number and developmental competence of oocytes by pre-treatment with FSH indicates that maturation in vitro is not limited by the growth phase of follicles in the ovaries. Normally one or two follicles become dominant in the ovulatory cycle and the other antral follicles cease growth and will enter atresia as the follicular phase progresses. There seems little detectable difference in the maturational and developmental competence of oocytes recovered from the dominant follicle or those from atretic follicles, a surprisingly common observation that was first made by Moor and Trounson (1977) in sheep follicle culture. There would be no clinical application of pre-treatment of women with FSH to collect immature oocytes, unless a very substantial benefit could be demonstrated for maturation and development to term. Such a benefit appears to be unlikely from the present data. It would also seem unlikely that pre-treatment with FSH after removal of the dominant follicle, a protocol demonstrated to maximize bovine embryo production, would be similarly beneficial when applied to women (Bousquet et al., 1999; Fig. 2 ).
Maturation of oocytes from untreated women
The human ovary contains numerous antral follicles during the follicular and luteal phase of the ovulating cycle and during pregnancy. The harvest of immature oocytes from antral follicles visible in the ovarian cortex provides the opportunity to study the maturation process in vitro and to avoid the administration of gonadotrophins to women for collection of multiple oocytes. Reports to date of maturation in vitro of human oocytes from untreated women are summarized (Tables 5 and 6 ).
It was originally shown by Cha et al. (1991) that oocytes recovered from ovaries removed from women for various gynaecological conditions can be matured in culture in Ham's F10 medium with 20% fetal cord serum (FCS) or 50% follicular fluid from preovulatory follicles that contained mature metaphase II oocytes. Maturation in Trounson et al. (1994) allowed greater access to growing follicles in the ovaries and the examination of an alternative to administration of high doses of gonadotrophins to women for superovulation. In EMEM with 10% FBS, 75 miu hMG ml -1 , 500 miu hCG ml -1 and 1 g oestradiol ml -1 , 81% of oocytes matured to metaphase II by 48−54 h of culture. The replacement of EMEM with TCM 199 produced the same outcomes for maturation, fertilization and embryo development, including births from maturation in both media (Trounson et al., 1994; Barnes et al., 1995 Barnes et al., , 1996 . These studies again confirmed that oocyte-cumulus health (tight cumuluscorona cover, loose or partly absent corona cover, denuded oocytes, obvious atresia in cumulus-corona cover; Fig. 4 ) had no obvious effect on maturational or developmental competence (Barnes et al., 1996) . It was apparent that oocytes from women with regular ovulatory cycles had a better cleavage rate than those who were anovulatory or had irregular menstrual cycles (Barnes et al., 1996) . Russell et al. (1997) claimed that administration of oestradiol to patients in the early to mid-follicular phase before recovery of immature oocytes, increases maturation, fertilization and their developmental competence. However, in controlled studies reported by Trounson et al. (1998) there was no benefit of oestrogen treatment of patients in any of the parameters examined. It is possible that prolonged oestrogen treatment may increase uterine receptivity for embryo implantation, although this remains to be proven.
In an interesting variation of natural cycle IVF, Thornton et al. (1998) recovered immature GV oocytes from follicles secondary to the one dominant follicle after hCG injection (10 000 iu). These follicles were р 12 mm and were matured in Ham's F10 + 50% follicular fluid as described by Cha et al. (1991) or in standard culture medium. There was no difference in maturation rates in vitro (30% and 32%, respectively) or fertilization rates (77% and 62%, respectively). A birth resulted from the transfer of an embryo in the same cycle as the immature egg retrieval. An additional birth resulted from one of six transfers of cryopreserved embryos derived from oocytes matured in vitro. A similar approach was adopted by Chian et al. (1999a Chian et al. ( ,b, 2000 for PCOS patients with irregular menstrual cycles, and good pregnancy rates were achieved using maturation medium with gonadotrophins and serum additives.
It has also been reported that oocytes recovered at the end of pregnancy (Caesarean section) can be matured in human tubal fluid (HTF) medium with 150 miu hMG ml -1 , 10% FCS and 1 g oestradiol ml -1 (Hwu et al., 1998) . Embryos failed to cleave beyond two to six cells in HTF medium with 10% FCS, but 26% of the pronuclear zygotes developed to blastocysts in human ampullary epithelial cell co-culture. This finding again demonstrates the flexibility of the origins of oocytes for maturation and underlines the importance of factors intrinsic to oocyte nuclear and cytoplasmic health for developmental competence. Providing culture medium and culture conditions are appropriate and suitable for maintaining the essential metabolism, growth and molecular expression patterns, a viable embryo can be obtained from a wide range of physiological and endocrine states. The challenge is to recognize the key elements intrinsic to oocyte maturational competence and to ensure that these are catered for in the interventions required for oocyte maturation in vitro. A recent examination of oocytes recovered after superovulation in humans, or after ovulation in mice, for molecular markers of apoptosis does not support the hypothesis that apoptosis is responsible for fertilization and developmental abnormalities (Van Blerkom and Davis, 1998) . Hence the cytoplasmic and chromosomal defects that occur in human oocytes are unlikely to be preprogrammed at least by apoptotic mechanisms. The occurrence of these defects may be due to interventions that interrupt the completion of essential cellular processes and interfere with messages from support cells required for molecular and cytoplasmic maturation events.
Developmental competence of in vitro matured oocytes
Nuclear maturation, the resumption of meiosis and completion of the first meiotic division, occurs in vitro for all species studied to date. Significant numbers of immature oocytes can be matured to metaphase II. Subsequent fertilization, cleavage and development to viable offspring vary according to the species studied. However, aberrations in cytoplasmic maturation are more likely to be apparent as failure in later stages of development (Moor et al., 1998) . It is of interest to note the improved rates of fertilization and embryo development and viability after administering a priming dose of hCG to patients, and further research is needed to determine the physiological mechanisms involved in the apparent improvement in cytoplasmic maturation of human oocytes in vitro. Recently, Anderiesz et al. (2000a) showed that exposure of cattle and human oocytes to a 1:10 ratio of FSH:LH (1 iu rhFSH ml -1 and 10 iu rhLH ml -1 ) resulted in significantly higher developmental competence evident by increased development to the blastocyst stage in vitro compared with FSH alone (1 iu rhFSH ml -1 ) or no gonadotrophins. In the human maturation system, FSH (1 iu rhFSH ml -1 in TCM 199 + 2 mg human serum albumin ml -1 ) was used for the first 24 h of culture and both 1 iu FSH ml -1 and 10 iu LH ml -1 were included for the remaining 24 h of culture to complete maturation. The biphasic addition of gonadotrophins may enable the maturation of LH receptors on cumulus and granulosa cells and improve their responsiveness to LH in the second culture phase. In these experiments, 24% of the fertilized oocytes developed to blastocysts in vitro and no blastocysts were obtained in maturation medium containing FSH alone or no gonadotrophins. Further experiments are needed to confirm the benefit of biphasic exposure of human oocytes to gonadotrophins and to determine the mechanism responsible for improved development of embryos. Development of bovine blastocysts was highest (24%) in medium with an FSH:LH ratio of 1:10, but since these blastocysts mature within 24 h, biphasic exposure to gonadotrophins was not examined.
It is important that evaluation of oocyte maturation in humans includes an adequate assessment of developmental competence in vivo or in vitro. Very few studies of in vitro matured human oocytes have included an assessment of development to the blastocyst stage at which stage it can be revealed that preimplantation development is seriously compromised (see for example Fig. 5) . Barnes et al. (1995) were the first to report successful development to the blastocyst stage in sequential culture medium designed specifically to optimize blastocyst development. A pregnancy resulted from the transfer of a single blastocyst after assisted hatching. However, only one of six embryos produced in this case study was competent to develop to the blastocyst stage. Hwu et al. (1998) demonstrated that embryos derived from in vitro matured oocytes when cultured in HTF culture medium alone arrest at the 2-to 16-cell stage of development. However, when embryos are co-cultured with human ampullary cells, 30% of zygotes are capable of developing to the blastocyst stage. Cobo et al. (1999) similarly reported high rates of development of embryos derived from in vitro matured oocytes to the blastocyst stage (49%) when embryos were co-cultured with endometrial epithelial cells. These recent reports compare favourably with the proportion of zygotes developing to the blastocyst stage in the absence of co-cultured cells from in vivo matured oocytes harvested from stimulated cycles.
Molecular checkpoint controls in oocyte maturation
The meiotic cell cycle is a dynamic system that functions via an elaborate sequence of highly ordered and interrelated events. Mammalian oocytes are arrested at the G2-phase of the cell cycle, specifically at the dictyate stage of prophase in the first meiotic division. The resumption of oocyte maturation releases oocytes from this developmental arrest and re-initiates meiosis. The meiotic cell cycle then proceeds through two consecutive M-phases, which result in a reduction in the maternal genome. The passage through the cell cycle is regulated by checkpoints and molecular controls.
Checkpoint controls
Cell cycle checkpoints are genetically encoded controls and biochemical pathways that represent an important mechanism in cell cycle progression as they impose delays in the cell cycle to ensure the systematic completion of each cell cycle phase before the initiation of the next phase (Hartwell and Weinert, 1989) . In somatic cells, there are three major checkpoints, which are present at G1, G2 and M-phase and specifically monitor cell size, DNA replication, DNA damage and spindle abnormalities.
Checkpoints responsive to cell size
Human oocytes must reach a critical size before they gain the ability to progress from the G2 to the M-phase. Whether the inability of small oocytes to progress through the G2-phase to M-phase is due to checkpoints responsive to cell size is unclear. Studies by Canipari et al. (1984) indicate that it is cell maturity rather than cell size that may govern meiotic progression. Alternatively, the inhibition of meiotic maturation in small oocytes may be due to a deficiency in products required for meiotic progression.
Checkpoints responsive to DNA replication
Genes have been identified that function as checkpoints for DNA damage and arrest, or delay cell cycle progression until DNA replication is complete (Table 7) . Fulka et al. (1994 Fulka et al. ( , 1995a demonstrated that the G2 to M-phase transition in murine oocytes is not influenced by the presence of unreplicated or replicating DNA. Although the genes associated with the checkpoint monitoring DNA replication have not been investigated directly in mammalian oocytes, current data indicate that the replication 66 A. Trounson et al. responsive checkpoints that function during mitosis do not function during oocyte meiosis (Fulka et al., 1994) . On the basis of these findings it is possible that human oocytes also lack the checkpoints responsive to DNA replication.
Checkpoints responsive to DNA damage Mammalian homologues to the yeast genes involved in the DNA damage checkpoints have been identified (Table  8) and are thought to participate in the same checkpoint functions as their yeast counterparts. Human oocytes have not been examined directly for the presence and function of these highly conserved DNA damage checkpoints. However, Fulka et al. (1997) demonstrated that the presence of damaged chromatin did not prevent the progression of meiosis in fused mouse oocytes. Therefore, it appears that DNA damage checkpoints may be either functionally inactive or absent during mammalian oocyte meiosis (Fulka et al., 1994 (Fulka et al., , 1997 .
Spindle sensitive checkpoints
Gene homologues to the spindle-sensitive checkpoints of yeast have been isolated in somatic cells of higher species (Table 9 ). However, relatively few studies have examined the presence of spindle associated checkpoints in the meiotic cell cycle of oocytes (Fulka et al., 1994 (Fulka et al., , 1995a LeMarie-Adkins et al., 1997; Cross and Smythe, 1998) . Xenopus oocytes were shown to contain a spindle assembly checkpoint, part of which was p42 MAP kinase (Cross and Smythe, 1998 ). Fulka et al. (1994 , 1995b demonstrated the presence of checkpoints in murine M-phase oocytes that can delay or accelerate meiotic progression, but LeMarie-Adkins et al. (1997) found that the checkpoint mechanism that functions at the metaphase to anaphase transition was absent in mouse oocytes.
Molecular control of oocyte maturation
Maturation promoting factor/M-phase promoting factor (MPF)
In addition to checkpoint controls, cell cycle progression is also regulated by endogenous products. The most common and widely studied factor in the area of cell cycle progression is maturation promoting factor (MPF). The original research by Masui and Markert (1971) led to the discovery that an activity in the cytoplasm of mature amphibian oocytes could induce meiosis when injected into G2 arrested frog oocytes. This activity was found to be MPF and it is now widely accepted that MPF is the primary molecule involved in meiotic cell cycle progression and the factor responsible for M-phase induction in all eukaryotic cells.
MPF is a serine−threonine kinase protein heterodimer composed of a catalytic subunit, p34 cdc2 , and a regulatory subunit, cyclin B (Labbe et al., 1989; Pines and Hunter, 1989; Gautier et al., 1990) . During the cell cycle, MPF activity is regulated by the phosphorylation−dephosphorylation of p34 cdc2 and its association with cyclin B (Clarke and Karsenti, 1991) . Specifically, MPF activation involves the association of cyclin B and p34 cdc2 and selective dephosphorylation of p34 cdc2 on two residues, tyrosine 15 (Tyr15) and threonine 14 (Thr14) (Gautier et al., 1988 (Gautier et al., , 1990 Dunphy and Newport, 1989) . This dephosphorylation is mediated by the cdc25 and nim1 genes (Russell and Nurse, 1986; Gautier et al., 1991) . In oocytes, MPF activation occurs initially at the G2 to M-phase transition. However, before the induction of M-phase, p34 cdc2 and cyclin B are present as pre-MPF, a bound and p34 cdc2 phosphorylated protein heterodimer, and are present in this inactivated state because of interaction with the WEE1 gene (Parker et al., 1991) (Fig. 6 ). Cyclic MPF activity is a characteristic feature of oocytes and is attributable to the periodic activation and inactivation of the MPF heterodimer. MPF activity is detected just before, or concomitantly with, GVBD. MPF activity increases until metaphase I and decreases during the anaphase to telophase transition. The activity increases again until the oocyte reaches metaphase II, and is maintained at a high level by the interaction of cytostatic factor (CSF) and the viral oncogene c-mos until fertilization. Inactivation of MPF results in exit from metaphase, and during oocyte maturation MPF inactivation occurs at the transition of metaphase I to anaphase I and again at fertilization. P34 cdc2 phosphorylation (Dorée et al., 1989) and cyclin degradation (Murray et al., 1989) are both required for MPF inactivation. However, despite the fact that both events are required for the cessation of M-phase, the proteolytic destruction of cyclin B is seen as the principal event associated with the inactivation of MPF activity (Glotzer et al., 1991) .
Cyclin destruction requires the presence of intact microtubules and occurs via ubiquitin-mediated proteolysis, a process that involves the attachment of ubiquitin molecules to the cyclin and is mediated in oocytes by three enzymes, E1, E2-C and E3 (Hershko et al., 1994) . The ubiquinated cyclin is presented to the proteasome for degradation. The factors that activate the cyclin proteolytic pathway have not yet been fully elucidated. However, it has been demonstrated that cyclin degradation can be triggered by cdc2 (Felix et al., 1990; Hershko et al., 1994) . Alternatively, the calcium, calmodulin, CaM kinase II pathway presents itself as an alternative candidate for initiating cyclin degradation because the calcium ionophore has been demonstrated to activate the proteasome (Kawahara and Yokosawa, 1994) and CaM kinase II activates cyclin destruction and mos and CSF degradation (Whitaker, 1996) . The calcium, calmodulin, CaM kinase II pathway probably represents the mechanism by which MPF is inactivated at fertilization.
MPF is activated in vivo at the onset of oocyte maturation in response to an endogenous LH surge. Mammalian oocytes resume meiotic maturation spontaneously in vitro upon liberation from the ovarian follicle. Our studies show that in vitro maturation of human oocytes activates MPF activity, as evidenced by the increase in histone H1 kinase activity at metaphase II (Fig. 7) . This finding demonstrates that MPF is activated in vitro in a manner similar to that for oocytes in vivo. . Diagrammatic representation of the molecular structure and activation of maturation promoting factor (MPF). MPF is shown as a heterodimer composed of p34 cdc2 and cyclin B. In its pre-MPF state, the MPF heterodimer is phosphorylated on tyrosine 15 (Tyr15) and threonine 14 (Thr14). Threonine 14 and tyrosine 15 phosphorylation is due to the action of hypo-phosphorylated wee1. Then activation of MPF is primarily due to the interplay between cdc25 and nim1 and wee1. The phosphorylated form of cdc25 is responsible for dephosphorylating the cdc2 protein on Tyr15 and Thr14, thus activating MPF. Hypo-phosphorylated wee1 prevents MPF activation by maintaining the Tyr15 and Thr14 residues of the cdc2 protein in a phosphorylated form. Nim1 maintains wee1 in a hyper-phosphorylated form that is unable to phosphorylate the Tyr15 and Thr14 residues of the cdc2 protein and thereby prevents wee1 from holding MPF in a phosphorylated and inactive form. The active MPF molecule is dephosphorylated on Tyr15 and Thr14 of the cdc2 protein and the cyclin protein is phosphorylated. The active form of MPF displays cdc2 kinase activity, known as histone H1 kinase activity. (Frankel and Fischinger, 1976) . The c-mos proto-oncogene encodes a serine−threonine protein kinase (mos), which is expressed in oocytes. In the oocyte, mos is involved in several aspects of oocyte maturation. Mos has been demonstrated to phosphorylate cyclin B (Roy et al., 1990 ) and thereby affects cyclin stability (O'Keefe et al., 1991; Xu et al., 1992) and MPF activity. As part of the CSF complex, mos is involved in the maintenance of metaphase II arrest in mammalian oocytes and similarly, in Xenopus oocytes, mos has been implicated in the pathway that is involved in metaphase arrest (Kosako et al., 1994) . In Xenopus, murine and bovine oocytes, mos activates mitogen activated protein (MAP) kinase (Nebreda and Hunt, 1993; Fissore et al., 1996; Verlhac et al., 1996) . In addition, mos initiates and regulates meiotic maturation in Xenopus oocytes (Sagata et al., 1988; Roy et al., 1996) and has been shown to participate in, but is not essential for, murine oocyte maturation (O'Keefe et al., 1989; Araki et al., 1996) . However, it is important for murine oocyte spindle and chromosome morphology, assembly and function (Zhao et al., 1991; Verlhac et al., 1996) .
Mos has been detected in human oocytes (Pal et al., 1994; Heikinheimo et al., 1995 Heikinheimo et al., , 1996 and its expression is restricted to the oocyte, as both the mos protein and mRNA are degraded during embryonic development (Heikinheimo et al., 1995) . Although the action of mos during human oocyte maturation in vitro has not been investigated directly, it is likely to play a role in the regulation of meiotic maturation by interacting with cyclin B and CSF to stabilize MPF and maintain meiotic arrest, as well as participate in the activation of MAP kinase.
Mitogen activated protein (MAP) kinase MAP kinase, which is alternatively known as extracellular regulated kinase (ERK), is a serine−threonine kinase that is activated via a protein kinase cascade at the onset of oocyte maturation in Xenopus (Haccard et al., 1990) , mouse (Verlhac et al., 1993) and pig (Inoue et al., 1995) oocytes. MAP kinase activity (ERK) is associated with the induction of meiosis in Xenopus oocytes (Haccard et al., 1995) and although activated at the onset of oocyte maturation in mice, MAP kinase is not necessarily required for GVBD in mouse oocytes (Sun et al., 1999a) . However, MAP kinase activity is associated with a plethora of cytoplasmic events including the regulation of microtubule dynamics, spindle assembly and chromosome condensation (Verlhac et al., 1993 (Verlhac et al., , 1994 Dedieu et al., 1996) . In most oocytes (clam, starfish and ascidian oocytes are the notable exceptions), high concentrations of MAP kinase are maintained during meiotic progression to metaphase II and concentrations decrease after fertilization (Ferrell et al., 1991; Dedieu et al., 1996) .
In human oocytes, p42ERK2 is the main form of MAP kinase (Sun et al., 1999b) . The activation pattern of MAP kinase in human oocytes is reminiscent of MAP kinase activity in other mammalian species such as pigs and mice. In humans, MAP kinase is inactive in immature oocytes, active in mature oocytes and the activity decreases after pronuclei formation after fertilization (Sun et al., 1999b) . Therefore, although not widely studied in human oocytes, it appears that the MAP kinase pattern of activation in the cell cycle is similar to that of other mammalian species and, therefore, MAP kinase may serve a similar function during human oocyte maturation.
Transcription and translation
During the period of oocyte growth a large number of genes are transcribed and translated (Schultz, 1986 Fair et al., 1995) . Thus, it is commonly accepted that transcription and translation play an integral role in meiotic progression and subsequent embryo developmental competence.
Although it is clear that immature human oocytes retrieved from unstimulated ovaries can mature from the GV stage to metaphase II in vitro, their subsequent embryonic development appears to be severely compromised (Trounson et al., 1994 (Trounson et al., , 1998 Barnes et al., 1996; Moor et al., 1998) . It has been suggested that the reduced developmental potential in human oocytes matured in vitro may be attributable to sub-optimal culture conditions, incomplete oocyte growth or abnormal cytoplasmic maturation (Moor et al., 1998) .
Studies on protein content have revealed that in vitro matured metaphase II human oocytes, derived from ovaries of untreated women (IVM group), display a reduced protein content compared with in vivo matured metaphase II oocytes retrieved from ovaries of gonadotrophin treated patients (VIVO group). The one-dimensional protein profiles of single human metaphase II stage oocytes from the IVM and VIVO groups following silver staining are presented (Fig. 8) . The human IVM oocytes have a reduced protein content compared with the VIVO group. Areas 1, 3, 4, 5 and 6 represent regions in which there appears to be an absence of particular proteins. Isoelectric focusing and SDS-PAGE were used in combination to isolate and identify further variations in particular oocyte proteins. When the protein profiles of IVM and VIVO human oocytes were examined by two-dimensional SDS-PAGE there were nine specific human oocyte proteins expressed in the VIVO group that were not detected in the IVM group. A number of proteins cannot be detected in human oocytes matured in vitro and these are likely to include molecules essential for cell cycle regulation and normal embryo development. A reduction in oocyte protein content after in vitro maturation has also been reported in bovine oocytes (Kastrop et al., 1991) . Whether these protein deficiencies are attributable to transcriptional inadequacies or translational defects is currently unknown.
Measurements of protein synthesis (Schultz et al., 1979; Salustri and Matrinozzi, 1983) reveal that oocytes cannot synthesize all the proteins they require during the growth phase (Schultz, 1986) . Part of the protein content of the oocyte may be obtained from proteins taken up from serum (Glass, 1971) . Alternatively, the follicular cells surrounding the oocyte could contribute to the protein content via a gap junction mediated transfer of molecules between the granulosa cells and the oocyte. Premature liberation of oocytes from small growing follicles may prevent the accumulation of follicular fluid proteins or cumulus cell transfer of proteins essential for developmental competence.
The available data indicate that in vitro matured human oocytes have a reduced protein content and the isolation and identification of the specific proteins that are either absent or at lower than required concentrations are needed.
Control of progression of maturation in vitro and developmental competence
Human oocytes appear to be unsynchronized in their response to maturational signals in vitro. This proposal is best demonstrated by the data reported by Trounson et al. (1994 Trounson et al. ( , 1998 . A small proportion of oocytes (15-20%) will extrude the first polar body by 24 h of culture, and by 43-47 h, 60% have matured to metaphase II. Similar data have been reported by Cha and Chian (1998) for oocytes obtained from untreated PCOS patients (Fig. 3) . As discussed earlier, the factor responsible for the resumption of meiotic maturation is MPF and its associated p34 cdc2 kinase activity is responsible for the cascade of events associated with meiotic maturation. The serine−threonine protein kinase inhibitor 6-dimethylaminopurine (DMAP) blocks GVBD and cell cycle progression in immature oocytes by inhibiting the post-translational dephosphorylation of p34 cdc2 that triggers MPF activity (Jessus et al., 1991) , but does not interfere with protein synthesis (Rime et al., 1989; Fulka et al., 1991) . Studies by Anderiesz et al. (2000b) have shown that DMAP in culture medium will reversibly block GVBD of mouse and human oocytes for 7 and 24 h, respectively. Removal of DMAP and subsequent culture in medium without DMAP results in the same timing of formation of metaphase II oocytes as the untreated controls (Anderiesz et al., 2000b) . It was hypothesized that DMAP treatment may synchronize nuclear maturational events in oocytes but there was no evidence of this effect in either mouse or human oocytes. DMAP treatment of human oocytes had no effect on fertilization or development to the blastocyst stage but decreased the developmental capacity of mouse embryos.
Prospects for the future application of human oocyte maturation in vitro
The recovery and maturation of oocytes from PCOS patients remains a very suitable alternative to surgery or diathermy of ovaries, for the establishment of pregnancy in these infertile women. It is apparent that large numbers of oocytes can be recovered by ultrasound-guided follicular aspiration and a reasonable pregnancy rate can be achieved when large numbers of unselected pronuclear or early cleavage stage embryos are transferred to the patients (Cha and Chian, 1998) . The selection of the more developmentally competent embryos by extended culture (day 3 to day 6) and preimplantation genetic diagnosis to remove embryo aneuploidies would reduce the number of embryos transferred but still retain an acceptable pregnancy rate. Clearly, improvements can be made to the maturation conditions for retention of the potential developmental competence of immature oocytes and this aim should continue to be a priority for research on oocyte maturation. The benefits for PCOS patients is to avoid the need to administer fertility drugs to induce superovulation for mature oocyte collection and IVF. PCOS patients are susceptible to OHSS (Danninger and Feichtinger, 1997) and recovery of immature oocytes and their maturation in vitro remains a very attractive treatment strategy for pregnancy.
The recovery of immature oocytes from patients who have been treated with high doses of gonadotrophins for IVF and in whom administration of hCG has been purposefully withheld is attractive because LH and hCG are potent inducers of vascular endothelial growth factor (VEGF), which is closely related to the initiation and exacerbation of OHSS. Follicular aspiration and recovery of immature oocytes has already been successful in such a case (Jaroudi et al., 1997) . This option could be adopted in clinical IVF to prevent the occurrence of OHSS.
It is also beneficial to recover oocytes from small nondominant follicles in natural ovulatory cycles, in patients that have had minimal ovarian stimulation with clomiphene citrate (Thornton et al., 1998; this review) or in PCOS patients with irregular menstrual cycles given progesterone for withdrawal bleeding, hCG at 10-14 days after progesterone and from which oocytes are recovered 36 h later (Chian et al., 1999a (Chian et al., ,b, 2000 . Oocytes from these small follicles (down to 7 mm diameter) appear to be developmentally competent and may contribute to successful pregnancy and development to term. This will be a new application for in vitro maturation and is obviously clinically useful for IVF patients wishing to avoid treatment with large doses of FSH, or for patients for whom superovulation treatment poses an unacceptable financial burden.
In the cases of recovering immature oocytes from follicles of patients at the normal time of ovulation, uterine receptivity for implantation and development will be similar to that for normal IVF patients or naturally cyclic women. The conditions required for uterine receptivity in anovulatory PCOS patients is not known and the use of progesterone for withdrawal bleeding may enhance implantation rates after embryo transfer.
